Abstract
Fat has been described to both accelerate and slow intestinal transit. We hypothesized that the fat-induced jejunal brake depends on the combined accelerating effect of CCK and the slowing effect of an opioid pathway. Using a multifistulated model, intestinal transit was measured in four dogs, while 60 mM oleate was delivered into the proximal gut with either 0 or 6 mg naloxone, and 0.1 mg/kg devazepide (a peripheral CCK-A-receptor antagonist) administered intraluminally and intravenously, respectively. In a second study, intestinal transit was measured in seven dogs, while naloxone was delivered intraluminally at 0-, 3-, 6-, or 12-mg doses. Compared to the jejunal brake (marker recovery of 50.1 ± 2.6%), intestinal transit was slowed by the CCK-A antagonist (36.4 ± 8.3%; P < 0.05) and accelerated by naloxone (82.0 ± 6.8%; P < 0.05). The accelerating effect of CCK occurred early in the transit response, while the dose-dependent effect (P < 0.05) of naloxone occurred later. We conclude that fat-induced jejunal brake depends on the early accelerating effect of CCK and the later slowing effect of a naloxone-sensitive opioid pathway.
Similar content being viewed by others
REFERENCES
Lin HC, Zhao XT, Wang L. Jejunal brake: inhibition of intestinal transit by fat in the proximal small intestine. Dig Dis Sci 41:326–329, 1996
Spiller RC, Trotman IF, Higgins BE, Ghatei MA, Grimble GK, Lee YC, Bloom SR, Misiewicz JJ, Silk DB: The ileal brake–inhibition of jejunal motility after ileal fat perfusion in man. Gut 25:365–374, 1984
Spiller RC, Trotman IF, Adrian TE, Bloom SR, Misiewicz JJ, Silk DB: Further characterisation of the ‘ileal brake’ reflex in man–effect of ileal infusion of partial digests of fat, protein, and starch on jejunal motility and release of neurotensin, enteroglucagon, and peptide YY. Gut 29:1042–1051, 1988
Borgstrom S, Arborelius M. Jr: Influence of a fatty acid on duodenal motility. Scand J Gastroenterol 10:599–601, 1975
Read NW, Al-Janabi MN, Edwards CA, Barber DC: Relationship between postprandial motor activity in the human small intestine and the gastrointestinal transit of food. Gastroenterology 86:721–727, 1984
Bennett S, Simmonds WJ: Absorptive capacity and intestinal motility in unanaesthetized rats during intraduodenal infusion of fat. Q J Exp Physiol 47:32–38, 1962
Lewis LD, Williams JA: Regulation of cholecystokinin secretion by food, hormones, and neural pathways in the rat. Am J Physiol 258:G512–G518, 1990
Douglas BR, Woutersen RA, Jansen JB, de Jong AJ, Lamers CB: The influence of different nutrients on plasma cholecystokinin levels in the rat. Experientia 44:21–23, 1988
Kleibeuker JH, Beekhuis HH, Jansen JMBJ, Piers DA, Lamers CBHW: Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin invest 18:173–177, 1998
Himeno S, Tarui S, Kanayama S, Kuroshima T, Shinomura Y, Hayashi C, Tateishi K, Imagawa K, Hashimura E, Hamaoka T: Plasma cholecystokinin responses after ingestion of liquid meal and intraduodenal infusion of fat, amino acids, or hydrochloric acid in man: analysis with region specific radioimmunoassay. Am J Gastroenterol 78:703–707, 1983
Parker JG, Beneventano TC: Acceleration of small bowel contrast study by cholecystokinin. Gastroenterology 58:679–684, 1970
Efsing HO, Lindroth B: Small bowel examination after injection of cholecystokinin. Clin Radiol 31:225–226, 1980
Vincent ME, Wetzner SM, Robbins AH: Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy 2:223–234, 1982
Schmidt WE, Creutzfeldt W, Schleser A, Choudhury AR, Nustede R, Hocker M, Nitsche R, Sostmann H, Rovati LC, Folsch UR: Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide. Am J Physiol 260:G197–G206, 1991
Zhao XT, Wang L, Lin HC: Slowing of intestinal transit by fat depends on naloxone-blockable efferent, opioid pathway. Am J Physiol 278:G866–G870, 2000
Lin HC, Doty JE, Reedy TJ, Meyer JH: Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient. Am J Physiol 256:G404–G411, 1989
Johansson C: Studies of gastrointestinal interactions. Scand J Gastroenterol 9(suppl 28):1–60, 1974
Dixon W: BMDP Statistical Software Manual. University of California Press, Berkeley, 1990
Schemann M, Siegle ML, Sahyoun H, Ehrlein HJ: Computer analysis of intestinal motility: effects of cholecystokinin and neurotensin on jejunal contraction patterns. J Gastroenterol 24:262–268, 1986
Rodriguez-Membrilla A, Martinez V, Vergar, P: Peripheral and central cholecystokinin receptors regulate postprandial intestinal motility in the rat. J Pharmacol Exp Ther 275:486–493, 1995
Green GM, Taguchi S, Friestman J, Chey WY, Liddle RA: Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat. Am J Physiol 256:G1016–G1021, 1989
Liddle RA, Goldfine ID, Rosen MS, Taplitz RA, Williams JA: Cholecystokinin bioactivity in human plasma. Molecular forms, responses to feeding, and relationship to gallbladder contraction. J Clin Invest 75:114–159, 1985
Pisegna JR, de Weerth A, Huppi K, Wank SA: Molecular cloning of the human brain and gastric cholecystokinin receptor: structure, functional expression and chromosomal localization. Biochem Biophys Res Commun 189:296–303, 1992
Chang RS, Lotti VJ: Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923–4926, 1986
Wank SA, Pisegna JR, de Weerth A: Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 89:8691–8695, 1992
Raybould HE, Tabrizi Y, Meyer JH, Walsh JH: PYY immunoneutralization does not alter lipid-induced inhibition of gastric emptying in rats. Regul Pept 79:125–130, 1999.
Mantyh CR, Pappas TN, Vigna, SR: Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. Gastroenterology 107:1019–1030, 1994
Holzer HH, Turkelson CM, Solomon TE Raybould HE: Intestinal lipid inhibits gastric emptying via CCK and a vagal capsaicin-sensitive afferent pathway in rats. Am J Physiol 267:G625–G629, 1994
De Giorgio R, Stanghellini V, Ricci Maccarini M, Morselli-Labate AM, Barbara G, Franzoso L, Rovati LC, Corinaldesi R, Barbara L, Go VL: Effects of dietary fat on postprandial gastrointestinal motility are inhibited by a cholecystokinin type A receptor antagonist. Ann NY Acad Sci 713:226–231, 1994
Feinle C, D'Amato M, Read NW: Cholecystokinin-A receptors modulate gastric sensory and motor responses to gastric distension and duodenal lipid. Gastroenterology 110:1379–1385, 1996
Burks TF, Hirning L, Galligan JJ, Davis, TP: Motility effects of opioid peptides in dog intestine. Life Sci 31:2237–2240, 1982
Oka T: Enkephalin (opiate) receptors in the intestine. Trends Pharmacol Sci 2:328–330, 1981
Zhao XT, Han TQ, Wang LJ, Lin HC: Fat-induced jejunal brake is blocked by naloxone in a dose-dependent fashion. Gastroenterology 110:A786, 1996
Zhao ZT, Han TQ, Lin HC: Slowing of intestinal transit by ileal fat is accelerated by naloxone delivered into jejunum but not ileum. Gastroenterology 110:A787, 1996
Owyang A, Sunshine AG, Reynolds JC: Caloric content of a meal affects duration but not contractile pattern of duodenal motility in man. Dig Dis Sci 34:528–536, 1989
Kinsman RI, Read NW: Effect of naloxone on feedback regulation of small bowel transit by fat. Gastroenterology 87:335–337, 1984
Read NW, McFarlane A, Kinsman RI, Bates TE, Blackhall NW, Farrar GB, Hall JC, Moss G, Morris AP, O'Neill B: Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 86:274–280, 1984
Lin HC, Zhao X-T, Wang L-J, Wong H: Fat-induced ileal brake depends on peptide YY. Gastroenterology 110:1491–1495, 1996
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, H.C., Zaidel, O. & Hum, S. Intestinal Transit of Fat Depends on Accelerating Effect of Cholecystokinin and Slowing Effect of an Opioid Pathway. Dig Dis Sci 47, 2217–2221 (2002). https://doi.org/10.1023/A:1020179009559
Issue Date:
DOI: https://doi.org/10.1023/A:1020179009559